Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
注射用BR61501治疗经标准治疗后失败或缺乏标准治疗的局部晚期或转移性恶性实体瘤患者中I期临床研究
[Translation] Phase I clinical study of BR61501 for injection in patients with locally advanced or metastatic malignant solid tumors who failed or lacked standard therapy
在经标准治疗失败(疾病进展或无法耐受)或缺乏标准治疗的晚期恶性实体肿瘤患者中确定注射用BR61501的最大耐受剂量(MTD)或II期推荐剂量(RP2D)及安全性。
[Translation] To determine the maximum tolerated dose (MTD) or phase II recommended dose (RP2D) and safety of BR61501 for injection in patients with advanced malignant solid tumors who failed standard therapy (disease progression or intolerance) or lacked standard therapy.
100 Clinical Results associated with Ningbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co Ltd
0 Patents (Medical) associated with Ningbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co Ltd
100 Deals associated with Ningbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co Ltd
100 Translational Medicine associated with Ningbo Meishan Bonded Port Area Belo Pharmaceutical Technology Co Ltd